drugset / Trial / NCT03629756
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with zimberelimab (AB122) (an anti-PD-1 antibody) in participants with advanced malignancies.
Timeline
- Start
- 2018-07-24
- Primary completion
- 2021-08-18
- Completion
- 2021-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etrumadenant | Small molecule | — | Oral |
| Subject | Zimberelimab | Monoclonal antibody | — | Intravenous |